# A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

> **NCT04991753** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 53 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **OTHER:** Placebo
- **DRUG:** Nipocalimab

## Key facts

- **NCT ID:** NCT04991753
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2022-08-10
- **Final completion:** 2022-08-10
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991753, "A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04991753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*